FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center.


Journal

Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 29 07 2017
accepted: 29 03 2018
pubmed: 29 5 2018
medline: 7 3 2019
entrez: 29 5 2018
Statut: ppublish

Résumé

Fluorescence in situ hybridization (FISH) is an important ancillary tool for the classification of bone/soft tissue (BST) tumors. The aim of this study was to evaluate the contribution of FISH to the final classification of common BST entities in the molecular pathology department of the Royal Prince Alfred Hospital (RPAH), which is one of the most important referral centers for the management of sarcomas in Australia. All routine diagnostic FISH tests performed on BST formalin-fixed paraffin embedded (FFPE) tissue specimens at the RPAH in a 5-year period (February, 2010-November, 2015) were reviewed. FISH analyses presented in this study include commercial break-apart probes (SS18, FUS, DDIT3, FUS, USP6, PDGFB, TFE3 and ALK) and a single enumeration (MDM2) probe. There were 434 interpretable FISH assays on BST samples including MDM2 (n=180), SS18 (n=97), FUS (n=64), DDIT3 (n=37), USP6 (n=30), PDGFB (n=13), TFE3 (n=8) and ALK (n=5). Discrepancies between the histopathological diagnosis and the FISH results were seen in 12% of the cases. In this subset of discordant cases, FISH contributed to the re-classification of 7% of cases originally diagnosed as synovial sarcoma (SS18) and 6% of adipocytic neoplasms (MDM2) based on the presence or absence of the expected gene alteration. Our study confirms that paraffin FISH is a sensitive and specific ancillary tool in the diagnosis of BST neoplasms when used in the appropriate clinicopathological context. These findings highlight the need for further ancillary molecular tools in the diagnosis and characterization of challenging cases.

Identifiants

pubmed: 29806089
doi: 10.1111/ajco.12980
doi:

Substances chimiques

Neoplasm Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-47

Subventions

Organisme : Cancer Institute NSW
Organisme : Breast Cancer Foundation
Organisme : Cancer Council NSW
ID : APP 1088778

Informations de copyright

© 2018 John Wiley & Sons Australia, Ltd.

Auteurs

Ana Cristina Vargas (AC)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Christina Selinger (C)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Laveniya Satgunaseelan (L)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Douglass Hanly Moir Pathology, Macquarie Park, New South Wales, Australia.

Wendy A Cooper (WA)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
School of Medicine, University of Western Sydney, Campbelltown, New South Wales, Australia.

Ruta Gupta (R)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Paul Stalley (P)

Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
Orthopaedic Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Macquarie University, New South Wales, Australia.
Westmead Kids, Sydney, New South Wales, Australia.
North Shore Private Hospital, St Leonards, New South Wales, Australia.

Wendy Brown (W)

Radiology/Medical Imaging, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Judy Soper (J)

Radiology/Medical Imaging, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Julie Schatz (J)

Radiology/Medical Imaging, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Richard Boyle (R)

Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
Orthopaedic Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Macquarie University, New South Wales, Australia.
Westmead Kids, Sydney, New South Wales, Australia.
North Shore Private Hospital, St Leonards, New South Wales, Australia.

David M Thomas (DM)

The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

Martin H N Tattersall (MHN)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.

Vivek Bhadri (V)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.

Fiona Maclean (F)

Douglass Hanly Moir Pathology, Macquarie Park, New South Wales, Australia.

Sally Fiona Bonar (SF)

Douglass Hanly Moir Pathology, Macquarie Park, New South Wales, Australia.
Westmead Kids, Sydney, New South Wales, Australia.
School of Medicine, Notre Dame University, Sydney, New South Wales, Australia.

Richard A Scolyer (RA)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Rooshdiya Z Karim (RZ)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Stanley W McCarthy (SW)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Annabelle Mahar (A)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Sandra A O'Toole (SA)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH